Janssen Biotech teams up with Vedanta Biosciences; deal expanded; Vedanta Regains Full Rights
Johnson & Johnson’s Janssen Biotech Inc. has allied with Vedanta Biosciences (focused on mucosal immunology) on the development of therapeutics that modulate pathways that interact between the human microbiome and immune system. As part of the deal, J&J's venture arm made an undisclosed equity investment in Vedanta.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com